JP Morgan Chase’s Alaunos Therapeutics TCRT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q3
– Sell
-778
Closed -$383K – 5773
2020
Q2
$383K Buy
778
+728
+1,456% +$325K ﹤0.01% 3965
2020
Q1
$18K Sell
50
-655
-93% -$339K ﹤0.01% 4974
2019
Q4
$499K Sell
705
-5,118
-88% -$3.52M ﹤0.01% 4240
2019
Q3
$3.74M Buy
5,823
+1,814
+45% +$1.44M ﹤0.01% 2930
2019
Q2
$3.45M Buy
4,009
+3,622
+936% +$2.49M ﹤0.01% 2938
2019
Q1
$223K Buy
+387
New +$162K ﹤0.01% 4590

Other funds holding TCRT

JP Morgan Chase's TCRT Position: Q3 2026 in Review

JP Morgan Chase opened a new position in Alaunos Therapeutics (TCRT) in Q3 2026: 7 shares worth $7. The stake represents ﹤0.01% of the portfolio and ranks #8081 among its holdings. This is a return to the name: JP Morgan Chase previously reported a position in TCRT as recently as Q2 2025.

JP Morgan Chase first reported a position in TCRT in Q2 2013 and has held it in 37 quarters since. The position peaked at $18.9M in Q1 2021. 31 funds tracked by Wall St. Rank hold TCRT as of Q3 2026.

  • JP Morgan Chase held 7 shares of Alaunos Therapeutics worth $7 as of Q3 2026.
  • Alaunos Therapeutics was a new JP Morgan Chase position in Q3 2026.
  • Alaunos Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q3 2026, its #8081 holding.
  • JP Morgan Chase first reported a position in Alaunos Therapeutics in Q2 2013 and has held it in 37 quarters since.
  • JP Morgan Chase's Alaunos Therapeutics position peaked at $18.9M in Q1 2021.
  • 31 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q3 2026.

Based on JP Morgan Chase's 13F filing for Q3 2026, filed 12 Nov 2026.